04-7193. Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Artemisinins With Improved Stability and Bioavailability for Therapeutic Drug Development and Application

AGENCY:

Department of the Army, DoD.

ACTION:

Notice.

SUMMARY:

In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 10/376,387 entitled “Artemisinins with Improved Stability and Bioavailability for Therapeutic Drug Development and Application,” filed February 27, 2003. Foreign rights are also available (PCT/US03/06283). The United States Government, as represented by the Secretary of the Army, has rights in this invention.

ADDRESSES:

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT:

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, [phone]. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, [phone], both at telefax [phone].

SUPPLEMENTARY INFORMATION:

A stable form of artemisinin wherein an artelinic acid or artesunic acid is complexed with cyclodextrin analogs, preferably, β-cyclodextrin. The complexed cyclodextrin artemisinin formulation shields the peroxide portion of the artemisinin backbone from hydrolytic decomposition rendering it stable in solution. Artelinic acid and cyclodextrin are placed into contact with one another to yield a 2:1 molecular species. Artesunic acid and cyclodextrin yield a 1:1 molecular species. The complexed cyclodextrin artemisinin formulation is effective for the treatment of malaria and is stable in solution for long periods of time.

Brenda S. Bowen,

Alternate Army Federal Register Liaison Officer.